Buying $1000 In ICLR: If an investor had bought $1000 of ICLR stock 15 years ago, it would be worth $12,763.95 today based on ...

Immatics N.V. (NASDAQ: IMTX, “Immatics”), a clinical-stage biopharmaceutical company active in the discovery and development of T cell-redirecting cancer immunotherapies, announced today the ...

NEW YORK, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) today reported monthly volumes for September 2024, as well as quarterly volumes, estimated revenue capture, number of listings, and ...

Stocks have moved moderately lower during trading on Thursday, giving back ground following the strong upward move seen in the ...

Data to be presented at IDWeek 2024 include: Presentation Title: Oral Sulopenem/probenecid for Uncomplicated Urinary Tract Infections (uUTI): Results from the REASSURE Trial Poster #: 1107 Presenter: ...

Kaiser Aluminum Corporation (NASDAQ: KALU) today announced that it plans to release its third quarter 2024 financial and operating results on Wednesday, October 23, 2024, after the market closes. The ...

Jefferies analyst Daniel Fannon maintained a Hold rating on Nasdaq (NDAQ – Research Report) today and set a price target of $68.00. The ...

CoStar Group (NASDAQ:CSGP – Get Free Report) was upgraded by equities research analysts at StockNews.com from a “sell” rating ...

In a report released today, William Katz from TD Cowen maintained a Hold rating on Nasdaq (NDAQ – Research Report), with a price target ...

Leading Video and AI-based Edge Computing Company Establishes U.S. Subsidiary to Accelerate Growth in the U.S. Defense and Homeland Security ...

SANTA BARBARA, Calif., Oct. 10, 2024 (GLOBE NEWSWIRE) -- AppFolio, Inc. (NASDAQ: APPF) today announced that it will report its third quarter 2024 financial results after the close of the U.S.

WOBURN, Mass., Oct. 09, 2024 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today ...